Published in Antimicrob Agents Chemother on July 02, 2012
Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet (2013) 2.80
Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis (2013) 2.29
Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One (2014) 1.32
The pyrazinamide susceptibility breakpoint above which combination therapy fails. J Antimicrob Chemother (2014) 1.31
Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy. Antimicrob Agents Chemother (2014) 1.13
Latent tuberculosis infection: myths, models, and molecular mechanisms. Microbiol Mol Biol Rev (2014) 1.06
Energy metabolism and drug efflux in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2014) 0.99
Biological variability and the emergence of multidrug-resistant tuberculosis. Nat Genet (2013) 0.97
Evolution of drug resistance in tuberculosis: recent progress and implications for diagnosis and therapy. Drugs (2014) 0.94
Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study. J Antimicrob Chemother (2014) 0.92
Does High-Dose Antimicrobial Chemotherapy Prevent the Evolution of Resistance? PLoS Comput Biol (2016) 0.89
Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model. Antimicrob Agents Chemother (2015) 0.89
Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients. Antimicrob Agents Chemother (2016) 0.86
A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies. EBioMedicine (2016) 0.85
Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease. Antimicrob Agents Chemother (2015) 0.84
Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection. Antimicrob Agents Chemother (2016) 0.80
Enhancement of antibiotic activity by efflux inhibitors against multidrug resistant Mycobacterium tuberculosis clinical isolates from Brazil. Front Microbiol (2015) 0.80
Novel adjunctive therapies for the treatment of tuberculosis. Curr Mol Med (2014) 0.80
Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease. Antimicrob Agents Chemother (2016) 0.79
Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease. Antimicrob Agents Chemother (2016) 0.79
Ion Channel Blockers as Antimicrobial Agents, Efflux Inhibitors, and Enhancers of Macrophage Killing Activity against Drug Resistant Mycobacterium tuberculosis. PLoS One (2016) 0.78
Resistance-Nodulation-Division Multidrug Efflux Pumps in Gram-Negative Bacteria: Role in Virulence. Antibiotics (Basel) (2013) 0.77
Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-resistant Mycobacterium massiliense Lung Disease. Antimicrob Agents Chemother (2016) 0.76
An upstream truncation of the furA-katG operon confers high-level isoniazid resistance in a Mycobacterium tuberculosis clinical isolate with no known resistance-associated mutations. Antimicrob Agents Chemother (2014) 0.76
Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. Antimicrob Agents Chemother (2015) 0.76
Genotypic and phenotypic detection of efflux pump in Rhodococcus equi. Braz J Microbiol (2014) 0.75
Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease. Antimicrob Agents Chemother (2016) 0.75
Thioridazine: A Non-Antibiotic Drug Highly Effective, in Combination with First Line Anti-Tuberculosis Drugs, against Any Form of Antibiotic Resistance of Mycobacterium tuberculosis Due to Its Multi-Mechanisms of Action. Antibiotics (Basel) (2017) 0.75
Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases. Antimicrob Agents Chemother (2016) 0.75
Pathogenic nontuberculous mycobacteria resist and inactivate cathelicidin: implication of a novel role for polar mycobacterial lipids. PLoS One (2015) 0.75
Mycobacterium tuberculosis Mutations Associated with Reduced Susceptibility to Linezolid. Antimicrob Agents Chemother (2016) 0.75
Determination of MIC Breakpoints for Second-Line Drugs Associated with Clinical Outcomes in Multidrug-Resistant Tuberculosis Treatment in China. Antimicrob Agents Chemother (2016) 0.75
Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis. Antimicrob Agents Chemother (2017) 0.75
Interplay between Mutations and Efflux in Drug Resistant Clinical Isolates of Mycobacterium tuberculosis. Front Microbiol (2017) 0.75
Efflux drug transporters at the forefront of antimicrobial resistance. Eur Biophys J (2017) 0.75
Treating tuberculosis with high doses of anti-TB drugs: mechanisms and outcomes. Ann Clin Microbiol Antimicrob (2017) 0.75
Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep (2009) 11.30
MYCOBACTERIA: LABORATORY METHODS FOR TESTING DRUG SENSITIVITY AND RESISTANCE. Bull World Health Organ (1963) 9.26
Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli. Proc Natl Acad Sci U S A (1980) 8.43
Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease. Lancet (2004) 6.84
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis (2006) 5.34
How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis (1998) 3.43
Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob Agents Chemother (1994) 3.28
Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis (2011) 3.05
Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis (2004) 2.95
Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest (2009) 2.78
Two compartment kinetic model with multiple artificial capillary units. J Antimicrob Chemother (1985) 2.62
Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis (2012) 2.60
Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob Agents Chemother (1995) 2.58
Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother (2002) 2.55
Macrolide efflux genes mef(A) and mef(E) are carried by different genetic elements in Streptococcus pneumoniae. J Clin Microbiol (2002) 2.23
Characterization of a genetic element carrying the macrolide efflux gene mef(A) in Streptococcus pneumoniae. Antimicrob Agents Chemother (2000) 2.21
Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother (2009) 2.15
Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am J Respir Crit Care Med (2011) 1.87
Structure and dissemination of a chromosomal insertion element encoding macrolide efflux in Streptococcus pneumoniae. J Infect Dis (2001) 1.79
A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob Agents Chemother (2009) 1.74
Molecular cloning and characterization of Tap, a putative multidrug efflux pump present in Mycobacterium fortuitum and Mycobacterium tuberculosis. J Bacteriol (1998) 1.72
Autopsy findings in AIDS patients with Mycobacterium avium complex bacteremia. J Infect Dis (1994) 1.61
Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. J Infect Dis (1996) 1.61
Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis (2010) 1.52
Tn2009, a Tn916-like element containing mef(E) in Streptococcus pneumoniae. Antimicrob Agents Chemother (2004) 1.52
Clinical significance and epidemiologic analyses of Mycobacterium avium and Mycobacterium intracellulare among patients without AIDS. J Clin Microbiol (2005) 1.30
Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother (2006) 1.26
A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs. Curr Opin Pharmacol (2011) 1.15
Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum. J Antimicrob Chemother (2005) 1.09
Mycobacterium avium complex infection in kidney transplant patients. Transpl Infect Dis (2005) 1.05
Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium. Antimicrob Agents Chemother (2010) 1.04
Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen. Antimicrob Agents Chemother (2006) 1.02
Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. Antimicrob Agents Chemother (2010) 1.01
Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains. Antimicrob Agents Chemother (2010) 1.01
Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor. Antimicrob Agents Chemother (2009) 0.96
Safety, toleration, and pharmacokinetics of intravenous azithromycin. Antimicrob Agents Chemother (1996) 0.95
In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother (2007) 0.94
Infection site concentrations: their therapeutic importance and the macrolide and macrolide-like class of antibiotics. Pharmacotherapy (2005) 0.93
Disseminated Mycobacterium avium complex: correlation between blood and tissue burden. J Infect Dis (1996) 0.92
A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin Infect Dis (1999) 0.89
Effect of drug concentration on emergence of macrolide resistance in Mycobacterium avium. Antimicrob Agents Chemother (2001) 0.88
A silent ABC transporter isolated from Streptomyces rochei F20 induces multidrug resistance. J Bacteriol (1998) 0.87
Pharmacokinetic/pharmacodynamic-based treatment of disseminated Mycobacterium avium. Future Microbiol (2011) 0.78
A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus. Clin Infect Dis (2000) 0.78
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis (2006) 5.34
Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis (2011) 3.05
A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients. Clin Infect Dis (2013) 2.89
Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis (2012) 2.60
Scalable signaling mediated by T cell antigen receptor-CD3 ITAMs ensures effective negative selection and prevents autoimmunity. Nat Immunol (2008) 2.34
Recommended education for pharmacists as competitive clinical scientists. Pharmacotherapy (2009) 2.31
Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis (2013) 2.29
Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother (2009) 2.15
Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother (2005) 2.07
An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob Agents Chemother (2010) 1.71
T-cell receptor signal transmission: who gives an ITAM? Trends Immunol (2003) 1.66
Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis (2010) 1.52
T cell receptor (TCR) clustering in the immunological synapse integrates TCR and costimulatory signaling in selected T cells. Proc Natl Acad Sci U S A (2005) 1.44
Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology (2010) 1.43
Pillars article: Sequential interactions of the TCR with two distinct cytoplasmic tyrosine kinases. Science. 1994. 263: 1136-1139. J Immunol (2014) 1.40
Spatiotemporal patterning during T cell activation is highly diverse. Sci Signal (2009) 1.33
Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother (2007) 1.28
The cytoplasmic tail of the T cell receptor CD3 epsilon subunit contains a phospholipid-binding motif that regulates T cell functions. J Immunol (2009) 1.22
Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling. Antimicrob Agents Chemother (2011) 1.17
A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs. Curr Opin Pharmacol (2011) 1.15
Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol (2008) 1.14
Acquired drug resistance because of pharmacokinetic variability in a young child with tuberculosis. Pediatr Infect Dis J (2014) 1.08
Drug concentration monitoring in Mycobacterium avium lung disease: problems with methods and conclusions. Am J Respir Crit Care Med (2013) 1.07
In vitro susceptibility testing and totally drug-resistant tuberculosis. Eur Respir J (2013) 1.06
The CD3 zeta subunit contains a phosphoinositide-binding motif that is required for the stable accumulation of TCR-CD3 complex at the immunological synapse. J Immunol (2011) 1.06
Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium. Antimicrob Agents Chemother (2010) 1.04
Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used. Antimicrob Agents Chemother (2010) 1.03
PTPH1 is a predominant protein-tyrosine phosphatase capable of interacting with and dephosphorylating the T cell receptor zeta subunit. J Biol Chem (2003) 1.03
Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners. Antimicrob Agents Chemother (2013) 1.02
Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. Antimicrob Agents Chemother (2010) 1.01
Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection. Antimicrob Agents Chemother (2012) 1.00
Meningeal tuberculosis: high long-term mortality despite standard therapy. Medicine (Baltimore) (2010) 0.98
Biological variability and the emergence of multidrug-resistant tuberculosis. Nat Genet (2013) 0.97
Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people. Antimicrob Agents Chemother (2011) 0.97
Signature MicroRNA expression patterns identified in humans with 22q11.2 deletion/DiGeorge syndrome. Clin Immunol (2013) 0.96
The membrane-proximal portion of CD3 epsilon associates with the serine/threonine kinase GRK2. J Biol Chem (2007) 0.96
Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med (2015) 0.96
Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people. Antimicrob Agents Chemother (2011) 0.95
The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations. Clin Infect Dis (2006) 0.94
The CD3 gamma epsilon/delta epsilon signaling module provides normal T cell functions in the absence of the TCR zeta immunoreceptor tyrosine-based activation motifs. Eur J Immunol (2005) 0.94
Transgenic expression of microRNA-185 causes a developmental arrest of T cells by targeting multiple genes including Mzb1. J Biol Chem (2013) 0.93
Haemophilus ducreyi targets Src family protein tyrosine kinases to inhibit phagocytic signaling. Infect Immun (2005) 0.92
Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy (2009) 0.92
Dynamic modulation of thymic microRNAs in response to stress. PLoS One (2011) 0.92
In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimens. Curr Pharm Des (2011) 0.90
In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis. Antimicrob Agents Chemother (2010) 0.89
New susceptibility breakpoints and the regional variability of MIC distribution in Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother (2012) 0.88
The formation and functions of the 21- and 23-kDa tyrosine-phosphorylated TCR zeta subunits. Immunol Rev (2003) 0.88
The protein tyrosine phosphatase PTPN4/PTP-MEG1, an enzyme capable of dephosphorylating the TCR ITAMs and regulating NF-kappaB, is dispensable for T cell development and/or T cell effector functions. Mol Immunol (2008) 0.87
Novel mutations in emb B gene of ethambutol resistant isolates of Mycobacterium tuberculosis: a preliminary report. Indian J Med Res (2008) 0.87
The constitutive tyrosine phosphorylation of CD3zeta results from TCR-MHC interactions that are independent of thymic selection. J Immunol (2007) 0.87
Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths. Antimicrob Agents Chemother (2013) 0.87
Invariant NKT cell development requires a full complement of functional CD3 zeta immunoreceptor tyrosine-based activation motifs. J Immunol (2010) 0.86
T cell antagonism is functionally uncoupled from the 21- and 23-kDa tyrosine-phosphorylated TCR zeta subunits. J Immunol (2003) 0.84
Basal and antigen-induced exposure of the proline-rich sequence in CD3ε. J Immunol (2011) 0.84
Haemophilus ducreyi LspA proteins are tyrosine phosphorylated by macrophage-encoded protein tyrosine kinases. Infect Immun (2008) 0.83
A novel missense mutation in the nuclear factor-κB essential modulator (NEMO) gene resulting in impaired activation of the NF-κB pathway and a unique clinical phenotype presenting as MRSA subdural empyema. J Clin Immunol (2010) 0.83
Scientific and patient care evidence to change susceptibility breakpoints for first-line anti-tuberculosis drugs. Int J Tuberc Lung Dis (2012) 0.81
Selective expression of the 21-kilodalton tyrosine-phosphorylated form of TCR zeta promotes the emergence of T cells with autoreactive potential. J Immunol (2005) 0.81
I-kappa B kinases alpha and beta have distinct roles in regulating murine T cell function. J Immunol (2002) 0.80
A formalized teaching, practice, and research partnership with the Veterans Affairs North Texas Health Care System: a model for advancing academic partnerships. Am J Pharm Educ (2009) 0.79
Pharmacokinetic/pharmacodynamic-based treatment of disseminated Mycobacterium avium. Future Microbiol (2011) 0.78
Reply to Moonan and Weis, Seaworth et al, and Nunn and Phillips. Clin Infect Dis (2013) 0.77
Predicting success in phase III studies from phase II results: a new paradigm is needed. J Clin Oncol (2008) 0.77
The Haemophilus ducreyi LspA1 protein inhibits phagocytosis by using a new mechanism involving activation of C-terminal Src kinase. MBio (2014) 0.76
Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop. J Pharmacokinet Pharmacodyn (2014) 0.76
CD81 interacts with the T cell receptor to suppress signaling. PLoS One (2012) 0.76
Mycobacterial shuttle vectors designed for high-level protein expression in infected macrophages. Appl Environ Microbiol (2012) 0.75
Adjuvant Therapy Choices in Patients With Resected Non-Small-Cell Lung Cancer: Correlation of Doctors' Treatment Plans and Relevant Phase III Trial Data. J Oncol Pract (2005) 0.75
AIDS orphans. N Engl J Med (2002) 0.75
Quantification of echodensities in tuberculous pericardial effusion using fractal geometry: a proof of concept study. Cardiovasc Ultrasound (2012) 0.75
Somatic mutations in telomerase promoter counterbalance germline loss-of-function mutations. J Clin Invest (2017) 0.75